|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Herpes Simplex Virus 2 (IgG),w/refl HSV-2 Inhib
Test Code17170
CPT Codes
86696
Preferred Specimen
Reject criteria: Gross hemolysis; Grossly lipemic; Plasma
PREFERRED
1 mL serum (SS, serum separator tube), room temperature
Minimum: 0.7 mL
--or--
ACCEPTABLE
1 mL serum (R, red-top tube (no gel)), room temperature
Minimum: 0.7 mL
RT: 7 days
Refrigerated (cold packs): 14 days
Frozen: 30 days
PREFERRED
1 mL serum (SS, serum separator tube), room temperature
Minimum: 0.7 mL
--or--
ACCEPTABLE
1 mL serum (R, red-top tube (no gel)), room temperature
Minimum: 0.7 mL
RT: 7 days
Refrigerated (cold packs): 14 days
Frozen: 30 days
Methodology
Immunoassay
Setup Schedule
Monday-Saturday Morning
Report available: Next Day
Report available: Next Day
Reference Range
See Laboratory Report
Clinical Significance
Herpes Simplex Virus (HSV) is responsible for several
clinically significant human viral diseases, with
severity ranging from inapparent to fatal. Clinical
manifestations include genital tract infections, neonatal
herpes, meningo-encephalitis, keratoconjunctivitis, and
gingivostomatitis. There are two HSV serotypes that are
closely related antigenically. HSV type 2 is more
commonly associated with genital tract and neonatal
infections, while HSV type 1 is more commonly associated
with infections of non-genital sites. Specific typing is
not usually required for diagnosis or treatment. The mean
time to seroconversion using the type specific assay is
25 days. The performance of this assay has not been
established for use in a pediatric population, for
neonatal screening, or for testing of immunocompromised
patients.
clinically significant human viral diseases, with
severity ranging from inapparent to fatal. Clinical
manifestations include genital tract infections, neonatal
herpes, meningo-encephalitis, keratoconjunctivitis, and
gingivostomatitis. There are two HSV serotypes that are
closely related antigenically. HSV type 2 is more
commonly associated with genital tract and neonatal
infections, while HSV type 1 is more commonly associated
with infections of non-genital sites. Specific typing is
not usually required for diagnosis or treatment. The mean
time to seroconversion using the type specific assay is
25 days. The performance of this assay has not been
established for use in a pediatric population, for
neonatal screening, or for testing of immunocompromised
patients.
